1
|
Zannier F, Angerilli V, Spolverato G, Brignola S, Sandonà D, Balistreri M, Sabbadin M, Lonardi S, Bergamo F, Mescoli C, Scarpa M, Bao QR, Dei Tos AP, Pucciarelli S, Urso ELD, Fassan M. Impact of DNA mismatch repair proteins deficiency on number and ratio of lymph nodal metastases in colorectal adenocarcinoma. Pathol Res Pract 2023; 243:154366. [PMID: 36774759 DOI: 10.1016/j.prp.2023.154366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 02/03/2023] [Accepted: 02/07/2023] [Indexed: 02/11/2023]
Abstract
BACKGROUND Approximately 15 % of colorectal adenocarcinomas (CRCs) are characterized by an altered expression of DNA mismatch repair (MMR) proteins (i.e. MMR deficiency [MMRd]). Lymph node ratio (LNR) represents one of the most important prognostic markers in non-advanced CRCs. No significant data are available regarding LNR distribution depending on MMR status. PURPOSE OF THE STUDY The aim of the present work was to compare pathological and clinical characteristics of MMRd tumors versus MMR proficient (MMRp) cases. Particular attention was paid to how these molecular sub-groups relate to the LNR. MATERIALS AND METHODS A mono-Institutional series of 1037 consecutive surgically treated stage I-IV CRCs were retrospectively selected and data were obtained from pathological reports. Cases were characterized for MMR/MSI status by means of immunohistochemistry or for microsatellite instability (MSI) analysis. RESULTS MMRd/MSI tumors (n = 194; 18.7 %) showed significant differences in comparison to MMRp lesions for sex (female prevalence 50.5 % vs 40.7 %; p = 0.013), age (74.2 vs 69.2; p < 0.001), location (right side; p < 0.001), diameter (larger than MMRp; p < 0.001), growth pattern (expansive pattern of growth; p < 0.001), peri- (p = 0.0002) and intra-neoplastic (p = 0.0018) inflammatory infiltrate, presence of perineural invasion (p < 0.001), stage (lower stage at presentation; p < 0.001), grade (higher prevalence of high-grade tumors; p < 0.001), and LNR (lower; p < 0.001). CONCLUSIONS MMRd/MSI tumors are a distinct molecular CRC subtype characterized by a significantly lower LNR in comparison to MMRp lesions. These data further support the prognostic impact of MMRd/MSI status in early-stage CRCs.
Collapse
Affiliation(s)
| | | | - Gaya Spolverato
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy
| | - Stefano Brignola
- Department of Pathology, Azienda ULSS 2 Marca Trevigiana, Treviso, Italy
| | - Daniele Sandonà
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy
| | | | - Marianna Sabbadin
- Department of Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Sara Lonardi
- Department of Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Francesca Bergamo
- Department of Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Claudia Mescoli
- Department of Medicine (DIMED), University of Padua, Padua, Italy
| | - Marco Scarpa
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy
| | - Quoc Riccardo Bao
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy
| | | | - Salvatore Pucciarelli
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy
| | - Emanuele L D Urso
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy
| | - Matteo Fassan
- Department of Medicine (DIMED), University of Padua, Padua, Italy; Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
| |
Collapse
|
2
|
Clemente N, Ciavattini A, Valenti G, Zannier F, Di Giuseppe J, Delli Carpini G, Fichera M, Del Fabro A, Giorda G, Goteri G, Canzonieri V, Sopracordevole F. Extramammary Paget's Disease of the Vulva and Concomitant Premalignant/Malignant Vulvar Lesions: A Potential Challenge in Diagnosis and Treatment. Curr Oncol 2023; 30:959-966. [PMID: 36661722 PMCID: PMC9857742 DOI: 10.3390/curroncol30010073] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 01/03/2023] [Accepted: 01/06/2023] [Indexed: 01/12/2023] Open
Abstract
The aim of the present study was to evaluate the incidence of concomitant vulvar cancers or premalignant lesions in women surgically treated for extramammary Paget's disease of the vulva (EMPDV) through a multicenter case series. The medical records of all women diagnosed with and treated for EMPDV from January 2010 to December 2020 were retrospectively analyzed. Women with EMPDV and synchronous vulvar cancer, vulvar intraepithelial neoplasia (VIN) and/or lichen sclerosus (LS) at the histology report were included in the study. A total of 69 women eligible for the present study were considered. Concomitant vulvar lesions occurred in 22 cases (31.9%). A total of 11 cases of synchronous VIN (50%) and 14 cases (63.6%) of concomitant LS were observed. One patient (4.5%) had synchronous vulvar SCC (FIGO stage 1B). Women with EMPDV and concomitant premalignant/malignant vulvar lesions had a significantly higher rate of invasive EMPDV and wider lesions with an extravulvar involvement. The specific meaning of the association between EMPDV, VIN, SCC and LS remains unclear. The potential overlapping features between different vulvar lesions highlight the importance of dedicated gynecologists and pathologists in referral centers.
Collapse
Affiliation(s)
- Nicolò Clemente
- Gynecological Oncology Unit, Centro di Riferimento Oncologico—National Cancer Institute, IRCCS, 33081 Aviano, Italy
| | - Andrea Ciavattini
- Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, 60123 Ancona, Italy
| | - Gaetano Valenti
- Gynecological Oncology Unit, Centro di Riferimento Oncologico—National Cancer Institute, IRCCS, 33081 Aviano, Italy
- Unit of Gynecology and Obstetrics, Department of Women’s and Children’s Health, Umberto I Hospital, 94100 Enna, Italy
| | - Federica Zannier
- Pathology Unit, Centro di Riferimento Oncologico—National Cancer Institute, IRCCS, 33081 Aviano, Italy
- Pathology Unit, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy
| | - Jacopo Di Giuseppe
- Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, 60123 Ancona, Italy
| | - Giovanni Delli Carpini
- Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, 60123 Ancona, Italy
| | - Mariasole Fichera
- Gynecological Oncology Unit, Centro di Riferimento Oncologico—National Cancer Institute, IRCCS, 33081 Aviano, Italy
- Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, 60123 Ancona, Italy
| | - Anna Del Fabro
- Gynecological Oncology Unit, Centro di Riferimento Oncologico—National Cancer Institute, IRCCS, 33081 Aviano, Italy
| | - Giorgio Giorda
- Gynecological Oncology Unit, Centro di Riferimento Oncologico—National Cancer Institute, IRCCS, 33081 Aviano, Italy
| | - Gaia Goteri
- Division of Pathological Anatomy, Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, 60123 Ancona, Italy
| | - Vincenzo Canzonieri
- Pathology Unit, Centro di Riferimento Oncologico—National Cancer Institute, IRCCS, 33081 Aviano, Italy
- Department of Medical, Surgical, and Health Sciences, University of Trieste, 34127 Trieste, Italy
| | - Francesco Sopracordevole
- Gynecological Oncology Unit, Centro di Riferimento Oncologico—National Cancer Institute, IRCCS, 33081 Aviano, Italy
| |
Collapse
|
3
|
Zannier F, Di Bella S, Della Torre S, Candido P, Pelliccione M, Della Vedova A, Cozzi C, Bollina R. Effects of three products in the prevention and treatment of chemotherapy and radiation therapy-induced oral mucositis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz238.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Belloni P, Cozzi C, Zannier F, Della Torre S, Toniolo D, Corradini G, Candido P, Bollina R. Weekly Epirubicin as palliative treatment in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
5
|
Zannier F, Belloni P, Toniolo D, Cozzi C. GelX Oral Gel and GelX Oral Spray (GOG&GOS) pain relief for oral mucositis. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv346.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Belloni P, Cozzi C, Toniolo D, Zannier F, Candido P, Della Torre S, Corradini G, Bollina R. Second-line chemoterapy in advanced gastric cancer patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.44] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Cognetta C, Bollina R, Toniolo D, Riva G, Belloni P, Cozzi C, Zannier F, della Torre S, Candido P, Corradini G, Bregni M. Cyberpsychology advantages: A training on a mobile phone to control stress and anxiety in a day hospital oncology nurses’ sample. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e16608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Corradini G, Candido P, Torre SD, Zannier F, Cozzi C, Belloni P, Toniolo D, Bollina R, Tagliaferro G. P108 Gemcitabine plus Oxaliplatin (GEMOXI): a feasible treatment in elderly patients with advanced pancreatic cancer. Crit Rev Oncol Hematol 2009. [DOI: 10.1016/s1040-8428(09)70146-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
9
|
Ferrari D, Rocca A, Oldani S, Zannier F, Tartaro T, Carbone C, Codecà C, Calabrese L, Chiesa F, Foa P. Safety and efficacy of the combination carboplatin and paclitaxel in patients (pts) with recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.15534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15534 Background: Pts with recurrent HNSCC have a dismal prognosis; treatment options are poorly effective and burdened with toxicity. In this clinical setting, cisplatin and paclitaxel have demonstrated activity despite relevant side effects. The purpose of this phase II trial was to investigate whether a combination of carboplatin and paclitaxel could offer a better toxicity profile without affecting efficacy. Methods: Pts with bi-dimensionally measurable disease, previously treated with induction chemotherapy (Cisplatin and 5-FU) followed by concomitant chemo-radiotherapy, were studied. Treatment consisted of Carboplatin AUC 5 and Paclitaxel 175 mg/m2 intravenously every 3 weeks. G-CSF and darbepoetin alpha were allowed in case of neutropenia (N < 1000/mm3) or anemia (Hb < 11 g/dL). Pts were evaluated for toxicity and response. Results: So far, 15 pts were enrolled. Median age was 53 yrs; ECOG P.S. was 0–1. Site of disease at relapse was head and neck excluding lips and sinus; 12 out of 15 pts had stage IV disease. All pts were evaluated for response and toxicity. After three cycles of chemotherapy, we observed 1 complete response (6.6%) and 7 partial responses (46.6%), with a 53.2 % overall response rate (95% CI 26.6–78.7%). Stable disease was seen in 2 patients (13.3%) and progressive disease was observed in 5 pts (33.3%). Toxicity was mild: we recorded 1 case of G3 toxicity (neutropenia) and no G4 side effects. Three pts experienced G1–2 neuropathy and 4 pts G1–2 hematologic toxicity (neutropenia and thrombocytopenia). Conclusions: The current regimen was feasible and effective. The combination of Carboplatin and Paclitaxel was well tolerated and could be safely administered to pts with recurrent HNSCC as second line treatment. Enrollment and data collection are still ongoing. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Ferrari
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| | - A. Rocca
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| | - S. Oldani
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| | - F. Zannier
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| | - T. Tartaro
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| | - C. Carbone
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| | - C. Codecà
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| | - L. Calabrese
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| | - F. Chiesa
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| | - P. Foa
- San Paolo Hospital, Milan, Italy; European Institute of Oncology, Milan, Italy
| |
Collapse
|
10
|
Balduzzi A, Zannier F, Maibach R, Dellapasqua S, Foa P, Colleoni M. Breast cancer in very old women: features of disease presentation. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80112-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
11
|
Zannier F. [Studies on the behavior of Helogale undulata rufula, a broom cat, in the Frankfurt Zoological Park]. Z Tierpsychol 1965; 22:672-95. [PMID: 5888490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|